FindTrial
Sign In

Influence of Dexmedetomidine on Incidence of Adverse Reactions Introduced by Hemabate in Postpartum Hemorrhage During Cesarean Section

Influence of Dexmedetomidine on Incidence of Adverse Reactions Introduced by Hemabate in Postpartum

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005316
Enrollment
Unknown
Registered
2014-07-23
Start date
2014-08-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section

Interventions

Placebo:intravenously physiological saline 20mL
Lower dose:lower dose (0.5ug kg-1) of dexmedetomidine
Higher dose:Higher dose (1ug kg-1) of dexmedetomidine

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were 20-40 years of age, height 155-170cm and capable of comprehending oral and written Chinese.

Exclusion criteria

Exclusion criteria: Exclusion criteria contained long-term opioid pain relieving utilization or NSAIDs, sedative utilization, mental illnesses, preoperative heart rate (HR) lower than 50bpm with atrial-ventricular conduction abnormalities or rhythm irregularities, neuromuscular and endocrine sicknesses or hypersensitive reactions to a2-adrenergic receptor agonists, or any past abdominal operation containing earlier caesarean delivery. Patients with coagulation issues or contraindications for receiving prostaglandin medications were additionally excluded from the study.

Design outcomes

Primary

MeasureTime frame
satisfaction score;—

Countries

China

Contacts

Public ContactJin Ni
drnijin@126.com+86 18902268256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026